Rybelsus vs Januvia: semaglutide or sitagliptin for type 2 diabetes

Rybelsus and Januvia are both once-daily tablets for type 2 diabetes that act on the body's GLP-1 system, but in different ways. Rybelsus contains semaglutide, a GLP-1 receptor agonist: a medicine that copies the gut hormone GLP-1¹. Januvia contains sitagliptin, a DPP-4 inhibitor, which boosts the body's own GLP-1 rather than adding a GLP-1 drug⁴. In PIONEER 3, the head-to-head trial, Rybelsus 7 mg and 14 mg lowered HbA1c and weight more than sitagliptin 100 mg at 26 weeks¹⁵. Sitagliptin is well tolerated with few stomach side effects and no fasting rules, but has a smaller effect on blood sugar and no weight loss¹⁵. The two are not normally combined: the American Diabetes Association advises against using a DPP-4 inhibitor with GLP-1-based therapy⁹. Which suits you is a decision for your prescriber.

In the US, the newer 1.5, 4 and 9 mg Rybelsus tablets are now sold as Ozempic tablets¹². See the Ozempic pill.

Rybelsus vs Januvia at a glance

Same hormone system, two different approaches

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. It makes the pancreas release more insulin and less glucagon, but only when blood sugar is raised¹. Both medicines use this system, which is sometimes called the incretin system after the gut hormones involved.

Rybelsus adds a GLP-1 medicine. Semaglutide is a modified version of human GLP-1 with 94% sequence similarity; it lasts about a week in the body, and it takes 4 to 5 weeks of daily tablets to reach steady levels¹. It also slightly slows stomach emptying¹.

Januvia works one step back. Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor: rather than adding a GLP-1 drug, it boosts the body's own GLP-1⁴.

The routines differ too. Rybelsus has to be swallowed on an empty stomach with up to 120 ml of plain water, followed by at least 30 minutes with no food, drink or other tablets¹; the UK and EU labels add a fast of at least 8 hours before the dose²³. Sitagliptin has no fasting rules¹⁵. See how to take Rybelsus.

PIONEER 3: the head-to-head trial

PIONEER 3 compared Rybelsus 3 mg, 7 mg and 14 mg with sitagliptin 100 mg in 1,864 adults with type 2 diabetes¹⁵. HbA1c is a blood test that reflects average blood sugar over recent months. At 26 weeks, in the US label's treatment-policy analysis (which counts everyone who started treatment, including people who stopped):

• HbA1c fell by 1.0 point on Rybelsus 7 mg and 1.3 points on 14 mg, against 0.8 points on sitagliptin¹.
• Weight fell by 2.2 kg on 7 mg and 3.1 kg on 14 mg, against 0.6 kg on sitagliptin¹.
• The 3 mg dose was not non-inferior to sitagliptin, meaning it was not shown to be at least as effective¹⁵. That fits the label, which says the 3 mg starting dose is not effective for blood sugar control and is there to reduce stomach side effects¹.

For context outside PIONEER 3, sitagliptin on its own lowered HbA1c by 0.6 points (18 weeks) and 0.8 points (24 weeks) more than placebo in monotherapy trials, and body weight did not increase⁴. Those are separate trials and should not be compared directly with PIONEER 3.

Why Rybelsus and Januvia are not usually combined

The American Diabetes Association's 2026 Standards of Care advise against combining a DPP-4 inhibitor with GLP-1-based therapy such as Rybelsus⁹. Both act through the GLP-1 system: Rybelsus by adding a GLP-1 receptor agonist, sitagliptin by boosting the body's own GLP-1¹⁴.

Rybelsus can be used with other kinds of diabetes medicine. The UK and EU licences allow it on its own when metformin is unsuitable, or in combination with other diabetes medicines²³. See Rybelsus vs metformin and Rybelsus vs Jardiance.

If you have been prescribed both, or are unsure whether a new medicine overlaps with one you already take, ask your prescriber or pharmacist. Do not stop either medicine on your own.

Heart outcomes: TECOS, PIONEER 6 and SOUL

A hazard ratio compares the rate of events between two groups; below 1 means fewer events in the group on the trial medicine, and close to 1 means little difference.

Sitagliptin. TECOS, its cardiovascular outcome trial, showed no increase or decrease in cardiovascular events (hazard ratio 0.98)⁶.

Rybelsus. PIONEER 6 (3,183 adults at high cardiovascular risk, median 15.9 months, compared with placebo) found major cardiovascular events in 3.8% on oral semaglutide and 4.8% on placebo (hazard ratio 0.79, 95% confidence interval 0.57 to 1.11). That showed safety, not benefit⁷. The later SOUL trial followed 9,650 adults aged 50 or over with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both for an average of 47.5 months, comparing oral semaglutide with placebo on top of standard care. Major cardiovascular events happened to 12.0% vs 13.8%, a hazard ratio of 0.86⁸. On that basis the FDA approved a US indication to reduce cardiovascular risk in adults with type 2 diabetes at high risk, on 17 October 2025¹³¹. In the EU and UK the SOUL results are in the product information without a separate indication³².

TECOS and SOUL had different populations and designs, so their results show what each found against its own comparison group, not how the two medicines compare.

Side effects, weight and cost

Rybelsus. The most common side effects are nausea, abdominal pain, diarrhoea, decreased appetite, vomiting and constipation¹. In placebo-controlled trials, any stomach or bowel side effect was reported by 41% on 14 mg against 21% on placebo, and 8% on 14 mg stopped because of them against 1%. Most nausea, vomiting and diarrhoea happened while the dose was being increased¹. Serious side effects include pancreatitis, gallbladder disease and kidney injury from dehydration after vomiting or diarrhoea¹. See Rybelsus side effects.

Sitagliptin. It is well tolerated, with few stomach side effects¹⁵. Its full side-effect list is in the Januvia leaflet⁴.

Low blood sugar. Rybelsus on its own has a low risk of hypoglycaemia (blood sugar falling too low), but the risk rises with insulin or a sulfonylurea, whose doses may need reducing¹².

Weight. Neither medicine is licensed for weight loss. Sitagliptin did not increase body weight in its monotherapy trials, while Rybelsus lowered weight more than sitagliptin in PIONEER 3⁴¹.

Cost. Merck says Januvia lost US market exclusivity in May 2026, and generic sitagliptin is widely listed in the UK at a much lower price than the brand¹⁰¹¹. For Rybelsus, see Rybelsus price and generic Rybelsus.